SCHEMBL6403718

SCHEMBL6403718

CCOC(=O)c1cnn(-c2ccc(Cl)cc2)c1C#N

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.55
RAB9A P51151 1/20 0.55
SMN1; SMN2 Q16637 3/20 0.54
TSHR P16473 1/20 0.54
HTT P42858 1/20 0.53
KMT2A Q03164 3/20 0.52
HPGD P15428 3/20 0.52
MEN1 O00255 2/20 0.52
MAPT P10636 2/20 0.52
LMNA P02545 1/20 0.52
GAA P10253 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
KDM4E B2RXH2 3/20 0.50
MAPK1 P28482 1/20 0.50
DRD2 P14416 1/20 0.50
DRD4 P21917 1/20 0.50
DRD3 P35462 1/20 0.50
NPY1R P25929 1/20 0.50
NPY2R P49146 1/20 0.50
USP2 O75604 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10340591 0.90 ALDH1A1 (0.68) ALDH1A1RAB9ASMN1; SMN2TSHRHTT
SCHEMBL10394019 0.89 HTT (0.54) ALDH1A1RAB9ASMN1; SMN2TSHRHTT
SCHEMBL10340580 0.88 ALDH1A1 (0.55) ALDH1A1RAB9ASMN1; SMN2TSHRHTT
SCHEMBL10340707 0.88 ALDH1A1 (0.55) ALDH1A1RAB9ASMN1; SMN2TSHRHPGD
SCHEMBL10340537 0.87 ALDH1A1 (0.68) ALDH1A1RAB9ASMN1; SMN2TSHRHTT
SCHEMBL10340634 0.87 HTT (0.53) ALDH1A1RAB9ASMN1; SMN2TSHRHTT
SCHEMBL10340616 0.87 HTT (0.71) ALDH1A1RAB9ASMN1; SMN2TSHRHTT
SCHEMBL10340547 0.86 HTT (0.52) ALDH1A1RAB9ASMN1; SMN2TSHRHTT
SCHEMBL10340593 0.85 KMT2A (0.57) ALDH1A1SMN1; SMN2TSHRHTTKMT2A
SCHEMBL5680826 0.84 ALDH1A1 (0.60) ALDH1A1RAB9ASMN1; SMN2TSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6916804-B2 Pyrimidine A2b selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2005-07-12 US disclosed
US-20050020564-A1 Pyrazole-amides and sulfonamides as sodium channel modulators ABBOTT LABORATORIES 2005-01-27 US disclosed
US-20040220170-A1 Pyrazole-amides and sulfonamides as sodium channel modulators ABBOTT LABORATORIES 2004-11-04 US disclosed
US-20030162764-A1 Pyrimidine A2b selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-08-28 US disclosed
EP-0177242-B1 POLLEN FORMATION INHIBITING PYRAZOLES ELI LILLY AND COMPANY (US) 1990-01-03 EP disclosed
US-4775409-A PREVENTING POLLEN FORMATION ELI LILLY AND COMPANY (US) 1988-10-04 US disclosed
US-4666504-A HYBRIDS ELI LILLY AND COMPANY (US) 1987-05-19 US disclosed
EP-0177242-A2 Pollen formation inhibiting pyrazoles ELI LILLY AND COMPANY (US) 1986-04-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162764-A1 Pyrimidine A2b selective antagonist compounds, their synthesis and use ADORA2B, ADORA2A, ADORA3 ALDH1A1 1491/4885RAB9A 3751/4885SMN1; SMN2 1908/4885
US-20050020564-A1 Pyrazole-amides and sulfonamides as sodium channel modulators SCN3A, KCNN3, TRPV3 ALDH1A1 3384/4885RAB9A 3662/4885SMN1; SMN2 395/4885
US-20040220170-A1 Pyrazole-amides and sulfonamides as sodium channel modulators SCN3A, KCNN3, TRPV3 ALDH1A1 3384/4885RAB9A 3662/4885SMN1; SMN2 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.